## Rebecca Kelsey

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4736790/publications.pdf

Version: 2024-02-01

1937457 1872570 93 92 4 6 citations h-index g-index papers 93 93 93 216 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Abnormal gyrification patterns present before symptoms in C9orf72 expansion carriers. Nature Reviews Neurology, 2019, 15, 434-434.	4.9	O
2	Antibiotic use might increase risk of ALS. Nature Reviews Neurology, 2019, 15, 492-492.	4.9	0
3	Predicting progression to AD using a deep-learning model. Nature Reviews Neurology, 2019, 15, 492-492.	4.9	1
4	Different clinical profiles in Huntington disease show distinct patterns of brain alterations. Nature Reviews Neurology, 2019, 15, 492-492.	4.9	1
5	Decreased NREM sleep linked with tauopathy. Nature Reviews Neurology, 2019, 15, 126-127.	4.9	0
6	Gene editing shows promise in LCA10. Nature Reviews Neurology, 2019, 15, 126-126.	4.9	1
7	Phase II trial of evobrutinib in multiple sclerosis. Nature Reviews Neurology, 2019, 15, 434-434.	4.9	0
8	ADAM10 inhibition shows promise in HD. Nature Reviews Neurology, 2019, 15, 434-434.	4.9	0
9	Arctic an unexpected hotspot for viral diversity. Nature Reviews Microbiology, 2019, 17, 398-398.	13.6	0
10	Filamentous bacteriophages affect pathogenicity of Pseudomonas infections in cystic fibrosis. Nature Reviews Microbiology, 2019, 17, 398-398.	13.6	0
11	Magnetotactic symbiosis in marine sediments. Nature Reviews Microbiology, 2019, 17, 398-398.	13.6	0
12	Distinct tau filaments in CTE. Nature Reviews Neurology, 2019, 15, 308-309.	4.9	0
13	Perivascular spaces are associated with cognition. Nature Reviews Neurology, 2019, 15, 246-247.	4.9	1
14	Arginine dimethylation is increased in patients with ALS and can predict disease progression. Nature Reviews Neurology, 2019, 15, 246-246.	4.9	0
15	Dimethyl fumarate is more effective than teriflunomide in preventing relapse in RRMS. Nature Reviews Neurology, 2019, 15, 246-246.	4.9	0
16	Complete withdrawal more feasible and effective than restriction in medication-overuse headache. Nature Reviews Neurology, 2019, 15, 188-188.	4.9	0
17	New blood-based biomarkers for Alzheimer disease. Nature Reviews Neurology, 2019, 15, 188-188.	4.9	2
18	Genetic variant associated with stroke outcomes. Nature Reviews Neurology, 2019, 15, 188-188.	4.9	1

#	Article	IF	CITATIONS
19	Increased α-synuclein levels in patients with sleep apnoea might be involved in PD pathogenesis. Nature Reviews Neurology, 2019, 15, 246-246.	4.9	2
20	Exploring vascular $\hat{Al^2}$ pathology using microvessel extracts from frozen human brain samples. Nature Reviews Neurology, 2019, 15, 186-186.	4.9	0
21	Prolonging the integrated stress response could be beneficial in multiple sclerosis. Nature Reviews Neurology, 2019, 15, 126-126.	4.9	0
22	Lifestyle factors and progression of PD. Nature Reviews Neurology, 2019, 15, 126-126.	4.9	1
23	Prodromal symptoms might vary between multiple sclerosis subtypes. Nature Reviews Neurology, 2019, 15, 186-186.	4.9	1
24	Iron deposition in periaqueductal grey matter as a biomarker of chronic migraine. Nature Reviews Neurology, 2019, 15, 186-186.	4.9	1
25	BAT is involved in control of satiation. Nature Reviews Endocrinology, 2019, 15, 1-1.	4.3	2
26	Macropinocytosis for proliferation. Nature Reviews Urology, 2018, 15, 336-337.	1.9	3
27	Solo PSA test does not lower mortality. Nature Reviews Urology, 2018, 15, 263-263.	1.9	2
28	Enzalutamide–cabazitaxel interactions. Nature Reviews Urology, 2018, 15, 69-69.	1.9	0
29	Glycolysis and AR expression as biomarkers. Nature Reviews Urology, 2018, 15, 2-2.	1.9	6
30	NPC mutations cause SRNS. Nature Reviews Nephrology, 2018, 14, 720-720.	4.1	0
31	ASK1 inhibition shows potential in DKD. Nature Reviews Nephrology, 2018, 14, 658-658.	4.1	3
32	Blocking CD122 might improve outcomes. Nature Reviews Nephrology, 2018, 14, 720-720.	4.1	0
33	The importance of residual complexity. Nature Reviews Drug Discovery, 2018, 17, 470-470.	21.5	0
34	Foxy–5 in prostate cancer model. Nature Reviews Urology, 2017, 14, 638-638.	1.9	5
35	Potential of PARP inhibition plus ADT in prostate cancer. Nature Reviews Urology, 2017, 14, 640-640.	1.9	0
36	Long-term outcomes of TRMDSC for chronic orchialgia. Nature Reviews Urology, 2017, 14, 700-700.	1.9	0

#	Article	IF	Citations
37	Autophagy in bladder exstrophy. Nature Reviews Urology, 2017, 14, 642-642.	1.9	O
38	SRRM4 drives NEPC progression. Nature Reviews Urology, 2016, 13, 371-371.	1.9	2
39	Mirabegron for paediatric OAB. Nature Reviews Urology, 2016, 13, 181-181.	1.9	0
40	Gut microbiome is unique in kidney stone disease. Nature Reviews Urology, 2016, 13, 368-368.	1.9	6
41	Anti-PD-1 antibodies: effective in GCTs?. Nature Reviews Urology, 2016, 13, 238-238.	1.9	0
42	Models to detect high-grade cancer. Nature Reviews Urology, 2016, 13, 301-301.	1.9	0
43	MCT4 is a novel target for prostate cancer. Nature Reviews Urology, 2016, 13, 123-123.	1.9	4
44	Novel drug for renal cell carcinoma. Nature Reviews Urology, 2016, 13, 6-6.	1.9	1
45	Expelling stones with ultrasonic propulsion. Nature Reviews Urology, 2016, 13, 7-7.	1.9	0
46	Urinary microRNA profiling for predicting UCB recurrence. Nature Reviews Urology, 2016, 13, 182-183.	1.9	1
47	Sunitinib versus everolimus for non-clear-cell renal cell carcinoma. Nature Reviews Urology, 2016, 13, 124-124.	1.9	1
48	PD-L1: a promising target for TGCTs. Nature Reviews Urology, 2016, 13, 62-62.	1.9	1
49	Selfish spermatogonia. Nature Reviews Urology, 2016, 13, 181-181.	1.9	O
50	'Stem-like' prostate basal cells. Nature Reviews Urology, 2016, 13, 238-238.	1.9	3
51	Avoiding unnecessary MRIs. Nature Reviews Urology, 2016, 13, 62-62.	1.9	O
52	STHLM3 model for prostate cancer screening. Nature Reviews Urology, 2016, 13, 4-4.	1.9	0
53	Shockwaves for erectile dysfunction. Nature Reviews Urology, 2016, 13, 63-63.	1.9	1
54	Feasibility of water ablation for removal of prostate tissue. Nature Reviews Urology, 2015, 12, 652-652.	1.9	1

#	Article	IF	CITATIONS
55	Comparing AFS and TVT for stress urinary incontinence. Nature Reviews Urology, 2015, 12, 5-5.	1.9	1
56	Hypofractionation not associated with reduced toxicity. Nature Reviews Urology, 2015, 12, 126-126.	1.9	1
57	New imaging method to improve prostate cancer detection. Nature Reviews Urology, 2015, 12, 65-65.	1.9	O
58	Long-term outcomes of single BEP cycle. Nature Reviews Urology, 2015, 12, 7-7.	1.9	0
59	Docetaxel in high-risk disease. Nature Reviews Urology, 2015, 12, 358-358.	1.9	O
60	Phase I study shows potential of TRC105 in mCRPC. Nature Reviews Urology, 2015, 12, 6-6.	1.9	2
61	New ligand–receptor targets. Nature Reviews Urology, 2015, 12, 238-238.	1.9	O
62	Analysing prostate cancer biomarkers in voided urine. Nature Reviews Urology, 2015, 12, 538-538.	1.9	0
63	New gene panel for aggressive prostate cancer. Nature Reviews Urology, 2015, 12, 242-242.	1.9	1
64	Aliskiren might have a protective effect in testicular torsion–detorsion injury. Nature Reviews Urology, 2015, 12, 303-303.	1.9	0
65	P2Y6 blockade might help control bladder storage symptoms. Nature Reviews Urology, 2015, 12, 358-358.	1.9	1
66	HipA and multidrug tolerance in urinary tract infection. Nature Reviews Urology, 2015, 12, 474-474.	1.9	0
67	High-dose-rate brachytherapy as monotherapy in prostate cancer. Nature Reviews Urology, 2015, 12, 359-359.	1.9	O
68	BCOR mutations that might help in diagnosis of CCSK. Nature Reviews Urology, 2015, 12, 416-416.	1.9	1
69	APOL1 gene variants associated with renal allograft failure. Nature Reviews Urology, 2015, 12, 238-238.	1.9	2
70	Dysregulated stress-related signalling pathways associated with lethality of prostate cancer. Nature Reviews Urology, 2015, 12, 652-652.	1.9	0
71	immunoPET for imaging disease progression in prostate cancer. Nature Reviews Urology, 2014, 11, 661-661.	1.9	0
72	Validating the new classification system for ANCA-associated GN. Nature Reviews Nephrology, 2013, 9, 433-433.	4.1	1

#	Article	IF	Citations
73	Protein network involved in maintaining kidney permeability. Nature Reviews Nephrology, 2013, 9, 64-64.	4.1	1
74	Is maintenance iron dosing associated with a lower infection risk than bolus dosing in haemodialysis patients?. Nature Reviews Nephrology, 2013, 9, 434-434.	4.1	0
75	Body fat distribution and renal risk. Nature Reviews Nephrology, 2013, 9, 309-309.	4.1	2
76	Enzyme replacement in Fabry disease. Nature Reviews Nephrology, 2013, 9, 125-125.	4.1	3
77	Is LDL-C level a good indicator of coronary risk in people with nondialysis-dependent CKD?. Nature Reviews Nephrology, 2013, 9, 369-369.	4.1	0
78	Urineâ€"but not serumâ€"suPAR might predict FSGS recurrence. Nature Reviews Nephrology, 2013, 9, 432-432.	4.1	2
79	Does sex affect risk associations?. Nature Reviews Nephrology, 2013, 9, 187-187.	4.1	0
80	Serious safety concerns regarding use of hydroxyethyl starch for acute fluid resuscitation. Nature Reviews Nephrology, 2013, 9, 185-185.	4.1	0
81	Tolvaptan in ADPKD—TEMPO 3:4 trial results. Nature Reviews Nephrology, 2013, 9, 1-1.	4.1	11
82	Patients with ESRD are at increased risk of complications and death after major elective vascular surgery. Nature Reviews Nephrology, 2013, 9, 248-248.	4.1	0
83	Ultrasound may be useful in preventing acute kidney injury. Nature Reviews Nephrology, 2013, 9, 556-556.	4.1	0
84	Epitope specificity responsible for MPO-ANCA pathogenicity. Nature Reviews Nephrology, 2013, 9, 310-310.	4.1	2
85	Use of altruistic nondirected donors in kidney transplant chains maximizes transplant numbers. Nature Reviews Nephrology, 2013, 9, 188-188.	4.1	1
86	Should CKD be considered as a coronary heart disease risk equivalent?. Nature Reviews Nephrology, 2012, 8, 431-431.	4.1	0
87	First catheter insertion for peritoneal dialysis—surgery versus radiology. Nature Reviews Nephrology, 2012, 8, 554-554.	4.1	0
88	Bone changes in children with chronic kidney disease. Nature Reviews Nephrology, 2012, 8, 682-682.	4.1	0
89	Investigating the role of BAFF in kidney graft dysfunction. Nature Reviews Nephrology, 2012, 8, 555-555.	4.1	2
90	Biocompatible versus standard PD solutionsâ€"more balANZ data. Nature Reviews Nephrology, 2012, 8, 613-613.	4.1	0

## REBECCA KELSEY

#	Article	IF	CITATIONS
91	Chronic kidney disease: a risk factor for stroke and bleeding in patients with atrial fibrillation. Nature Reviews Nephrology, 2012, 8, 551-551.	4.1	2
92	Ischaemic preconditioning for preventing contrast-induced AKI. Nature Reviews Nephrology, 2012, 8, 492-492.	4.1	2
93	Pre-emptive CMV therapy versus universal CMV prophylaxis in renal transplant recipients. Nature Reviews Nephrology, 2012, 8, 614-614.	4.1	O